Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases

Clinical candidate selection finalised for lead programme targeting mast-cell driven diseases Dermatology industry veteran Thibaud Portal, PhD appointed as CEO LONDON, March 30, 2023 /PRNewswire/ — Granular Therapeutics, (Granular) a private biotech company specialising in precision…